Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
Diego Villa, MD, FRCPC
Advertisement
Articles by Diego Villa, MD, FRCPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
Navigating New Horizons in Neuroendocrine Prostate Cancer
4
The Intersection of Technology and Psycho-Oncology Care
5